ORTINGLOBE · NSE
ORTIN GLOBAL LIMITED
₹15.83
-3.77% (-₹0.62)
Prev. close
₹16.45
Volume
8,090
Delivery %
69.6%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About ORTIN GLOBAL LIMITED
Ortin Global Limited engages in the manufacture and trading of pharmaceuticals, drugs, and intermediates in India. The company offers various pharmaceutical formulations of tablets, capsules, syrups, and dry powders; formulations, such as anti-diabetics, anti-allergics, anti-anginal and cardiovascular, sedatives and tranquilisers, anti-helmenthetics, analgesics and antipyretics, anti-biotics-quinolones, anti-biotic-pencillins, antifungal, cephalosporins, and macrolides. Its formulations also include chemo therapeutics, antacids and anti-ulcerants, anti-spasmodics, calcium and iron preparations, anti-arthritic drugs, protein supplements, enzymes, and vitamins, as well as psychiatry, appetizer, gynaec, and anti-retroviral products. In addition, the company offers active pharmaceutical ingredient (API) intermediates, including anti-retroviral, anti-diabetics, analgesics and antipyretics, anti-biotics, antifungal, antacids and anti-ulcerants, and anti-malarials; and manufactures fine chemicals, and grignard and alkali metal products. Further, the company provides services in the areas of process development, process and product characterization, analytical research and development, and assay development; research and development services for new formulation brands; and diagnostic services comprising development of rapid flow kits, assays, and reagents. Additionally, it undertakes long-term contracts for manufacturing intermediate and developing new APIs; operates as a merchant exporter of finished pharmaceutical formulations; and engages in real estate. The company also exports all types of medicines including ayurvedic, homeopathic, unani, biochemical, nature cure products. The company was formerly known as Ortin Laboratories Limited and changed its name to Ortin Global Limited in June 2024. Ortin Global Limited was incorporated in 1986 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Sanka Murali Krishna Murthy
Headquarters
Hyderabad
Employees
8
Website
ortinlabsindia.comExchange
View on NSE ↗Key stats
Market cap
₹12.87 Cr
EPS (TTM)
₹-1.11
Beta (1Y · daily vs NIFTY 50)
0.42
Beta (5Y · monthly vs NIFTY 50)
1.22
Shares float
58.97 L
EPS · quarter ended Jun 2026
₹-0.42
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.0% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹8.17 Cr | ₹8.23 Cr | ₹6.02 Cr | ₹2.11 Cr | ₹34.22 L | ₹10.05 L | |
| EBITDA | ₹1.30 Cr | ₹57.44 L | ₹48.47 L | ₹-6.36 Cr | ₹-82.31 L | ₹-72.07 L |
| ₹94.54 L | ₹-39.88 L | ₹-6.69 L | ₹-8.04 Cr | ₹-84.64 L | ₹-74.04 L | |
| Diluted EPS | ₹1.16 | ₹-0.49 | ₹-0.12 | ₹-9.89 | ₹-1.04 | ₹-0.91 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹21.27 Cr | ₹20.70 Cr | ₹21.20 Cr | ₹6.66 Cr | ₹3.78 Cr | ₹4.65 Cr | |
| ₹6.94 Cr | ₹6.14 Cr | ₹6.45 Cr | ₹1.81 Cr | ₹25.00 L | ₹1.01 Cr | |
| Stockholders' equity | ₹11.36 Cr | ₹10.96 Cr | ₹10.86 Cr | ₹2.82 Cr | ₹1.98 Cr | ₹1.24 Cr |
Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹18.03 Cr | ₹2.15 Cr | ₹-25.33 L | ₹-4.79 Cr | ₹-41.03 L | ₹-55.96 L | |
| Investing cash flow | ₹6.96 L | ₹-12.53 L | ₹-20,000 | ₹11.50 Cr | ₹-36,000 | ₹3.90 L |
| ₹-8.11 Cr | ₹-47.54 L | ₹90.40 L | ₹-3.49 Cr | ₹32.83 L | ₹75.28 L | |
| Capital expenditure | — | ₹-12.53 L | ₹-20,000 | — | ₹-36,000 | — |
| End cash position | — | ₹-3.92 Cr | ₹-3.24 Cr | ₹45.93 L | ₹37.37 L | ₹60.59 L |
Capital expenditure, End cash position have filed figures for only some of the years shown — the missing years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Dec 22(6Q) | Mar 23 | Jun 23–Dec 23(3Q) | Mar 24–Jun 26(10Q) |
|---|---|---|---|---|
| Promoter | 15.68% | 21.51% | 7.36% | 1.23% |
| Public | 84.32% | 78.49% | 92.64% | 98.77% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| ORTIN GLOBAL LIMITED | ₹14.11 Cr | ₹17.09 | — | 11.40 | -59.8% | 0.81 | -70.6% | -5.2% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 20
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.